Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
← catalyst calendarSponsored by Biodesix, Inc. (industry) · BDSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
25
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-18 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Nodule Solitary Pulmonary
- Non-small Cell Carcinoma
Primary outcome
what the primary-completion date above is the date OFLung Nodule Diagnosis
measured Up to 24 months
Permalink · BDSX's whole pipeline · Catalyst calendar · Every registered study · What changed